ストックスクリーナーアプリを入手
1.65
3.51%
-0.06
アフターアワーズ：
1.66
0.01
+0.61%
前日終値:
$1.71
開ける：
$1.72
24時間の取引高:
584.79K
Relative Volume:
0.55
時価総額：
$232.85M
収益：
$15.53M
当期純損益:
$-52.71M
株価収益率:
-3.2836
EPS:
-0.5025
ネットキャッシュフロー:
$-59.00M
1週間 パフォーマンス:
-9.84%
1か月 パフォーマンス:
-30.67%
6か月 パフォーマンス:
+4.43%
1年 パフォーマンス:
-20.29%
1日の値動き範囲:
$1.63
$1.72
1週間の範囲:
$1.63
$1.91
52週間の値動き範囲:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.65 | 232.85M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | Oppenheimer | Outperform |
| 2025-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-10 | アップグレード | Citigroup | Neutral → Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-29 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | ダウングレード | Stifel | Buy → Hold |
| 2022-02-01 | 開始されました | Raymond James | Strong Buy |
| 2021-05-03 | 開始されました | Stifel | Buy |
| 2021-03-25 | 繰り返されました | Citigroup | Buy |
| 2020-11-03 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-12-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-11-15 | 開始されました | Citigroup | Buy |
| 2018-09-19 | 開始されました | Evercore ISI | Outperform |
| 2017-09-26 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-06-20 | 開始されました | Chardan Capital Markets | Neutral |
| 2014-10-15 | 開始されました | Deutsche Bank | Buy |
| 2014-10-13 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Proqr Therapeutics N V (PRQR) 最新ニュース
ProQR names AI executives as clinical data nears By Investing.com - Investing.com Canada
ProQR Taps AI Leaders Chris Hart and Thomas Wolf to Accelerate Axiomer RNA Editing Pipeline - TipRanks
ProQR names AI executives as clinical data nears - Investing.com
Hugging Face co-founder joins ProQR (PRQR) to drive AI drug discovery - Stock Titan
Nvidia agreed to buy Hugging Face for $12.9B. Its co-founder will advise ProQR on AI. - Stock Titan
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media
ProQR Therapeutics N.V.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com
ProQR doses first participant in AX-0811 phase 1 trial - investing.com
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks
ProQR Announces First Participant Dosed in Phase 1 Study of - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com
ProQR at Cantor conference: RNA editing pipeline gains speed - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
Qiagen N.V.ADR Peer Comparison – Compare with Others - Value Research
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com Canada
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates ProQR stock rating on platform data - in.investing.com
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - KTVB
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks
ProQR Announces Second Quarter 2026 Operating and Financial Results - The Manila Times
Proqr Therapeutics N V (PRQR) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):